Cochrane · systematic review · CD006531
Paroxetine versus other anti‐depressive agents for depression
Purgato, M, Papola, D, Gastaldon, C, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Common Mental DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
133
current version
GRADE rated
93
No studies
1
Included studies
NR
No studies 1 · 0.8%Ungraded 39 · 29.3%Very low 0 · 0%Low 5 · 3.8%Moderate 86 · 64.7%High 2 · 1.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Paroxetine compared with older ADs for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs older ADs | OR 1.04 [0.92, 1.17] | 34 studies · 4647 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs older ADs | OR 0.9 [0.61, 1.33] | 4 studies · 526 participants | Low Downgraded: risk of bias |
Failure to respond at 16‐24 weeks Paroxetine vs older ADs | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs older ADs | OR 1.23 [0.49, 3.07] | 3 studies · 401 participants | Low Downgraded: risk of bias, inconsistency |
SMD at endpoint Paroxetine vs older ADs | no estimate extracted | 35 studies · 4745 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs older ADs | OR 0.84 [0.73, 0.96] | 44 studies · 6810 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs older ADs | OR 0.64 [0.54, 0.77] | 42 studies · 6132 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with agomelatine for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs agomelatine | OR 1.25 [0.78, 2.01] | 1 study · 284 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs agomelatine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 16‐24 weeks Paroxetine vs agomelatine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint HDRS Paroxetine vs agomelatine | OR 1.27 [0.75, 2.14] | 1 study · 284 participants | Moderate Downgraded: risk of bias |
SMD at endpoint HDRS Paroxetine vs agomelatine | no estimate extracted | 4 studies · 1074 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs agomelatine | OR 0.99 [0.57, 1.71] | 1 study · 284 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs agomelatine | OR 1.6 [0.99, 2.59] | 1 study · 284 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with amisulpride for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs amisulpride | OR 0.65 [0.36, 1.15] | 1 study · 277 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs amisulpride | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 16‐24 weeks Paroxetine vs amisulpride | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs amisulpride | OR 0.85 [0.49, 1.46] | 1 study · 277 participants | Moderate Downgraded: risk of bias |
SMD at endpoint Paroxetine vs amisulpride | no estimate extracted | 1 study · 272 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs amisulpride | no estimate extracted | 0 studies · 0 participants | Ungraded |
Participants with at least some Side Effects Paroxetine vs amisulpride | OR 1.49 [0.89, 2.5] | 1 study · 277 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with aprepitant for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs aprepitant | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 1‐4 weeks Paroxetine vs aprepitant | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 16‐24 weeks Paroxetine vs aprepitant | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs aprepitant | OR 1.57 [1.08, 2.29] | 4 studies · 807 participants | High |
SMD at endpoint Paroxetine vs aprepitant | no estimate extracted | 1 study · 102 participants | High |
Failure to complete ‐ any cause ‐ Paroxetine vs aprepitant | OR 1.53 [0.76, 3.09] | 1 study · 143 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs aprepitant | no estimate extracted | 0 studies · 0 participants | Ungraded |
Paroxetine compared with bupropion for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs bupropion | OR 0.73 [0.3, 1.79] | 1 study · 100 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs bupropion | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 16‐24 weeks Paroxetine vs bupropion | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs bupropion | no estimate extracted | 0 studies · 0 participants | Ungraded |
SMD at endpoint Paroxetine vs bupropion | no estimate extracted | 1 study · 132 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs bupropion | OR 1.16 [0.62, 2.2] | 2 studies · 240 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs bupropion | OR 1.6 [0.43, 5.92] | 1 study · 140 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with citalopram for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs citalopram | OR 1.54 [1.04, 2.28] | 1 study · 406 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs citalopram | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 16‐24 weeks Paroxetine vs citalopram | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs citalopram | no estimate extracted | NR | No studies |
SMD at endpoint Paroxetine vs citalopram | no estimate extracted | 1 study · 201 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs citalopram | OR 0.99 [0.61, 1.6] | 1 study · 406 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs citalopram | OR 0.74 [0.46, 1.21] | 1 study · 406 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with duloxetine for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs duloxetine | OR 0.89 [0.7, 1.14] | 6 studies · 1821 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs duloxetine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 16‐24 weeks Paroxetine vs duloxetine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs duloxetine | OR 0.98 [0.8, 1.19] | 6 studies · 1821 participants | Moderate Downgraded: risk of bias |
SMD at endpoint Paroxetine vs duloxetine | no estimate extracted | 6 studies · 1481 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs duloxetine | OR 0.97 [0.77, 1.23] | 6 studies · 1821 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs duloxetine | OR 0.81 [0.64, 1.01] | 6 studies · 1870 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with escitalopram for depression
Population: depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs escitalopram | OR 1.12 [0.76, 1.65] | 2 studies · 784 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs escitalopram | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 16‐24 weeks Paroxetine vs escitalopram | OR 1.36 [0.87, 2.12] | 1 study · 459 participants | Moderate Downgraded: risk of bias |
Failure to remit at endpoint Paroxetine vs escitalopram | OR 1.15 [0.6, 2.22] | 2 studies · 784 participants | Low Downgraded: risk of bias, inconsistency |
SMD at endpoint Paroxetine vs escitalopram | no estimate extracted | 2 studies · 772 participants | Low Downgraded: risk of bias, inconsistency |
Failure to complete ‐ any cause ‐ Paroxetine vs escitalopram | OR 1.47 [0.77, 2.79] | 2 studies · 784 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs escitalopram | OR 1.28 [0.86, 1.91] | 1 study · 454 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with fluoxetine for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs fluoxetine | OR 1.98 [0.79, 1.23] | 11 studies · 2418 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs fluoxetine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 16‐24 weeks Paroxetine vs fluoxetine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs fluoxetine | no estimate extracted | 0 studies · 0 participants | Ungraded |
SMD at endpoint Paroxetine vs fluoxetine | no estimate extracted | 9 studies · 2109 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ total drop out rate Paroxetine vs fluoxetine | OR 1.05 [0.89, 1.23] | 13 studies · 2798 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs fluoxetine | OR 0.94 [0.69, 1.28] | 9 studies · 2255 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with fluvoxamine for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs fluvoxamine | OR 1.19 [0.72, 1.94] | 3 studies · 261 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs fluvoxamine | OR 0.71 [0.41, 1.24] | 3 studies · 281 participants | Moderate Downgraded: risk of bias |
Failure to respond at 16‐24 weeks Paroxetine vs fluvoxamine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs fluvoxamine | OR 0.78 [0.44, 1.38] | 3 studies · 261 participants | Moderate Downgraded: risk of bias |
SMD at endpoint Paroxetine vs fluvoxamine | no estimate extracted | 1 study · 58 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs fluvoxamine | OR 0.96 [0.54, 1.72] | 3 studies · 261 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs fluvoxamine | OR 1.12 [0.42, 2.97] | 3 studies · 261 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with hypericum for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs hypericum | OR 1.6 [0.95, 2.69] | 1 study · 251 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs hypericum | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 16‐24 weeks Paroxetine vs hypericum | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs hypericum | OR 1.84 [1.11, 3.06] | 1 study · 251 participants | Moderate Downgraded: risk of bias |
SMD at endpoint Paroxetine vs hypericum | no estimate extracted | 1 study · 244 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs hypericum | OR 1.9 [0.98, 3.67] | 1 study · 251 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs hypericum | OR 2.6 [1.51, 4.46] | 1 study · 251 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with milnacipran for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs milnacipran | OR 0.93 [0.59, 1.47] | 1 study · 302 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs milnacipran | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 16‐24 weeks Paroxetine vs milnacipran | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs milnacipran | OR 0.92 [0.57, 1.49] | 1 study · 302 participants | Moderate Downgraded: risk of bias |
SMD at endpoint Paroxetine vs milnacipran | no estimate extracted | 1 study · 299 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs milnacipran | OR 1.17 [0.67, 2.3] | 2 studies · 343 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs milnacipran | OR 0.69 [0.41, 1.15] | 1 study · 302 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with mirtazapine for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs mirtazapine | OR 1.2 [0.9, 1.61] | 4 studies · 766 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs mirtazapine | OR 2.39 [1.42, 4.02] | 3 studies · 726 participants | Moderate Downgraded: risk of bias |
Failure to respond at 16‐24 weeks Paroxetine vs mirtazapine | OR 1.41 [0.81, 2.48] | 3 studies · 726 participants | Moderate Downgraded: risk of bias |
Failure to remit at endpoint Paroxetine vs mirtazapine | OR 1.52 [1.13, 2.06] | 4 studies · 766 participants | Moderate Downgraded: risk of bias |
SMD at endpoint Paroxetine vs mirtazapine | no estimate extracted | 1 study · 246 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs mirtazapine | OR 1.26 [0.91, 1.74] | 3 studies · 726 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs mirtazapine | OR 1.07 [0.76, 1.5] | 3 studies · 726 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with nefazodone for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs nefazodone | OR 0.31 [0.07, 1.25] | 1 study · 40 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs nefazodone | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 16‐24 weeks Paroxetine vs nefazodone | OR 0.64 [0.17, 2.38] | 1 study · 40 participants | Moderate Downgraded: risk of bias |
Failure to remit at endpoint Paroxetine vs nefazodone | no estimate extracted | 0 studies · 0 participants | Ungraded |
SMD at endpoint Paroxetine vs nefazodone | no estimate extracted | 2 studies · 235 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs nefazodone | OR 0.53 [0.11, 2.6] | 1 study · 40 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs nefazodone | OR 0.69 [0.34, 1.4] | 1 study · 206 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with reboxetine for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs reboxetine | OR 0.82 [0.66, 1.02] | 3 studies · 1369 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs reboxetine | OR 0.66 [0.5, 0.87] | 3 studies · 1375 participants | Moderate Downgraded: risk of bias |
Failure to respond at 16‐24 weeks Paroxetine vs reboxetine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs reboxetine | no estimate extracted | 0 studies · 0 participants | Ungraded |
SMD at endpoint Paroxetine vs reboxetine | no estimate extracted | 3 studies · 1291 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs reboxetine | OR 0.78 [0.51, 1.19] | 3 studies · 1375 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs reboxetine | OR 1.08 [0.74, 1.58] | 3 studies · 1375 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with sertraline for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs sertraline | OR 1.25 [0.89, 1.77] | 3 studies · 618 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs sertraline | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 16‐24 weeks Paroxetine vs sertraline | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs sertraline | OR 0.94 [0.67, 1.34] | 2 studies · 545 participants | Moderate Downgraded: risk of bias |
SMD at endpoint Paroxetine vs sertraline | no estimate extracted | 1 study · 353 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs sertraline | OR 1.37 [0.52, 3.6] | 2 studies · 426 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs sertraline | no estimate extracted | 0 studies · 0 participants | Ungraded |
Paroxetine compared with tianeptine for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs tianeptine | OR 1.04 [0.71, 1.53] | 3 studies · 648 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs tianeptine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 16‐24 weeks Paroxetine vs tianeptine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs tianeptine | OR 0.66 [0.18, 2.36] | 1 study · 44 participants | Moderate Downgraded: risk of bias |
SMD at endpoint Paroxetine vs tianeptine | no estimate extracted | 3 studies · 586 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs tianeptine | OR 1.46 [0.75, 2.85] | 3 studies · 648 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs tianeptine | OR 1.26 [0.89, 1.78] | 2 studies · 604 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with trazodone for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs trazodone | OR 0.71 [0.21, 2.41] | 1 study · 108 participants | Moderate Downgraded: risk of bias |
Failure to respond at 1‐4 weeks Paroxetine vs trazodone | OR 0.54 [0.25, 1.19] | 1 study · 108 participants | Moderate Downgraded: risk of bias |
Failure to respond at 16‐24 weeks Paroxetine vs trazodone | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs trazodone | OR 1.06 [0.47, 2.38] | 1 study · 108 participants | Moderate Downgraded: risk of bias |
SMD at endpoint Paroxetine vs trazodone | no estimate extracted | 1 study · 108 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs trazodone | no estimate extracted | 0 studies · 0 participants | Ungraded |
Participants with at least some Side Effects Paroxetine vs trazodone | OR 0.68 [0.3, 1.55] | 1 study · 108 participants | Moderate Downgraded: risk of bias |
Paroxetine compared with venlafaxine for depression
Population: patients with depression
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to respond at endpoint (6‐12 weeks) Paroxetine vs venlafaxine | OR 1.1 [0.58, 2.11] | 4 studies · 747 participants | Low Downgraded: risk of bias, inconsistency |
Failure to respond at 1‐4 weeks Paroxetine vs venlafaxine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to respond at 16‐24 weeks Paroxetine vs venlafaxine | no estimate extracted | 0 studies · 0 participants | Ungraded |
Failure to remit at endpoint Paroxetine vs venlafaxine | OR 1.57 [1.08, 2.29] | 4 studies · 807 participants | Moderate Downgraded: risk of bias |
SMD at endpoint Paroxetine vs venlafaxine | no estimate extracted | 2 studies · 411 participants | Moderate Downgraded: risk of bias |
Failure to complete ‐ any cause ‐ Paroxetine vs venlafaxine | OR 1.08 [0.82, 1.44] | 6 studies · 1079 participants | Moderate Downgraded: risk of bias |
Participants with at least some Side Effects Paroxetine vs venlafaxine | OR 1.01 [0.52, 1.95] | 2 studies · 200 participants | Moderate Downgraded: risk of bias |